The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The role of the electrocardiogram (ECG) in phase I drug development in patients with cancer: The University of Texas M. D. Anderson Cancer Center experience with 8,966 ECGs.
H. Veasey Rodrigues
No relevant relationships to disclose
A. Naing
No relevant relationships to disclose
D. S. Hong
No relevant relationships to disclose
G. S. Falchook
No relevant relationships to disclose
S. Fu
No relevant relationships to disclose
J. J. Wheler
No relevant relationships to disclose
A. M. Tsimberidou
No relevant relationships to disclose
S. L. Moulder
No relevant relationships to disclose
F. Janku
No relevant relationships to disclose
S. Wen
No relevant relationships to disclose
S. N. Fessahaye
No relevant relationships to disclose
E. C. Golden
No relevant relationships to disclose
D. I. Westerhold
No relevant relationships to disclose
M. Ewer
Consultant or Advisory Role - AstraZeneca; Genentech; Roche
Honoraria - Roche
R. Kurzrock
Honoraria - Merck
Research Funding - Merck